HA eases décolletage lines

Feeling more hydrated and having visibly fewer chest wrinkles are different outcomes. In its 7 October neck-care shopping feature, British Vogue described hydration but could not assess deep-line benefit. That distinction matters when considering what an injectable might add: a pleasant cosmetic impression is a different kind of evidence from a blinded wrinkle assessment.

A trial published on 9 October in Dermatologic Surgery offers a more specific answer for SB-NASHA, a hyaluronic acid gel, in moderate-to-severe décolletage wrinkles. At 12 weeks, 73.6% of the treated group improved by at least one grade on a five-point wrinkle scale, compared with 18.8% receiving no treatment. The 54.8-percentage-point difference is substantial, but it establishes a benefit against no treatment—not superiority to a cream, laser or another injectable.

## Improvement does not mean wrinkle-free

The evaluator assessing that primary outcome did not know the allocation. Participants and treating investigators did. Across two study stages, 192 women were randomized: 144 to treatment and 48 to the control group. The treatment was a course of three sessions, rather than a single appointment. The 12-week assessment followed the third session by four weeks.

A one-grade change could mean moving from severe to moderate wrinkles. It does not mean that lines disappeared, nor does it measure how much the change matters in someone's daily life. At weeks 24 and 32, response rates were 86.9% versus 34.9% and 80.8% versus 40.9%. Those later figures used available observations; unlike the primary analysis, they did not carry baseline scores forward for missing assessments. They should not be read as proof that the result grew stronger for everyone over time.

## Recovery belongs in the result

The full paper provides a more useful safety picture than the phrase “well tolerated” alone. After the first session, 92.4% recorded at least one predefined injection-site response in their diaries. Most symptoms were tolerable and resolved within one to two weeks.

Separately, investigators recorded treatment-related adverse events in 32 of 163 treated women, or 19.6%. All were mild or moderate; none was serious. Their median duration was 11.5 days, but the reported range extended to 432 days. The diary responses and investigator-recorded events are different measures and must not be added together. A mild classification also does not necessarily mean a brief inconvenience.

## Who the evidence represents

An additional 19 women with Fitzpatrick skin types V–VI were treated without randomization for safety evaluation only. Their inclusion does not establish equivalent wrinkle reduction in darker skin. The randomized population mainly had types I–IV, and the trial cannot settle uncommon risks.

Galderma funded the research and medical writing; four authors were employees, and the clinical authors disclosed industry relationships. Those ties do not erase the randomized result, but make independent confirmation valuable. The defensible conclusion is a measured wrinkle benefit after a three-session course in a selected population, with common local reactions and important questions about broader applicability—not a universal promise of a rejuvenated chest.